BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

287 related articles for article (PubMed ID: 20408841)

  • 1. Spectrum of molecular defects in juvenile myelomonocytic leukaemia includes ASXL1 mutations.
    Sugimoto Y; Muramatsu H; Makishima H; Prince C; Jankowska AM; Yoshida N; Xu Y; Nishio N; Hama A; Yagasaki H; Takahashi Y; Kato K; Manabe A; Kojima S; Maciejewski JP
    Br J Haematol; 2010 Jul; 150(1):83-7. PubMed ID: 20408841
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Genetic typing of CBL, ASXL1, RUNX1, TET2 and JAK2 in juvenile myelomonocytic leukaemia reveals a genetic profile distinct from chronic myelomonocytic leukaemia.
    Pérez B; Kosmider O; Cassinat B; Renneville A; Lachenaud J; Kaltenbach S; Bertrand Y; Baruchel A; Chomienne C; Fontenay M; Preudhomme C; Cavé H
    Br J Haematol; 2010 Dec; 151(5):460-8. PubMed ID: 20955399
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Correlation of clinical features with the mutational status of GM-CSF signaling pathway-related genes in juvenile myelomonocytic leukemia.
    Yoshida N; Yagasaki H; Xu Y; Matsuda K; Yoshimi A; Takahashi Y; Hama A; Nishio N; Muramatsu H; Watanabe N; Matsumoto K; Kato K; Ueyama J; Inada H; Goto H; Yabe M; Kudo K; Mimaya J; Kikuchi A; Manabe A; Koike K; Kojima S
    Pediatr Res; 2009 Mar; 65(3):334-40. PubMed ID: 19047918
    [TBL] [Abstract][Full Text] [Related]  

  • 4. ASXL1 mutation is associated with poor prognosis and acute transformation in chronic myelomonocytic leukaemia.
    Gelsi-Boyer V; Trouplin V; Roquain J; Adélaïde J; Carbuccia N; Esterni B; Finetti P; Murati A; Arnoulet C; Zerazhi H; Fezoui H; Tadrist Z; Nezri M; Chaffanet M; Mozziconacci MJ; Vey N; Birnbaum D
    Br J Haematol; 2010 Nov; 151(4):365-75. PubMed ID: 20880116
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Quantitative assessment of PTPN11 or RAS mutations at the neonatal period and during the clinical course in patients with juvenile myelomonocytic leukaemia.
    Matsuda K; Sakashita K; Taira C; Tanaka-Yanagisawa M; Yanagisawa R; Shiohara M; Kanegane H; Hasegawa D; Kawasaki K; Endo M; Yajima S; Sasaki S; Kato K; Koike K; Kikuchi A; Ogawa A; Watanabe A; Sotomatsu M; Nonoyama S; Koike K
    Br J Haematol; 2010 Feb; 148(4):593-9. PubMed ID: 19874312
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Characteristics of RAS pathway mutations in juvenile myelomonocytic leukaemia: a single-institution study from Korea.
    Kim HS; Lee JW; Kang D; Yu H; Kim Y; Kang H; Lee JM; Ahn A; Cho B; Kim S; Chung NG; Kim Y; Kim M
    Br J Haematol; 2021 Dec; 195(5):748-756. PubMed ID: 34590720
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Genome-wide single-nucleotide polymorphism analysis in juvenile myelomonocytic leukemia identifies uniparental disomy surrounding the NF1 locus in cases associated with neurofibromatosis but not in cases with mutant RAS or PTPN11.
    Flotho C; Steinemann D; Mullighan CG; Neale G; Mayer K; Kratz CP; Schlegelberger B; Downing JR; Niemeyer CM
    Oncogene; 2007 Aug; 26(39):5816-21. PubMed ID: 17353900
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Mutations of the PTPN11 and RAS genes in rhabdomyosarcoma and pediatric hematological malignancies.
    Chen Y; Takita J; Hiwatari M; Igarashi T; Hanada R; Kikuchi A; Hongo T; Taki T; Ogasawara M; Shimada A; Hayashi Y
    Genes Chromosomes Cancer; 2006 Jun; 45(6):583-91. PubMed ID: 16518851
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Juvenile myelomonocytic leukaemia and Noonan syndrome.
    Strullu M; Caye A; Lachenaud J; Cassinat B; Gazal S; Fenneteau O; Pouvreau N; Pereira S; Baumann C; Contet A; Sirvent N; Méchinaud F; Guellec I; Adjaoud D; Paillard C; Alberti C; Zenker M; Chomienne C; Bertrand Y; Baruchel A; Verloes A; Cavé H
    J Med Genet; 2014 Oct; 51(10):689-97. PubMed ID: 25097206
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Hemophagocytosis associated with leukemia: a striking association with juvenile myelomonocytic leukemia.
    Unal S; Cetin M; Kutlay NY; Elmas SA; Gumruk F; Tukun A; Tuncer M; Gurgey A
    Ann Hematol; 2010 Apr; 89(4):359-64. PubMed ID: 19798502
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Juvenile myelomonocytic leukemia with PTPN11 mutation in a 23-month-old girl.
    Jakovljević G; Kardum-Skelin I; Rogosić S; Nakić M
    Coll Antropol; 2010 Mar; 34(1):251-4. PubMed ID: 20432758
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Gene mutations in the Ras pathway and the prognostic implication in Korean patients with juvenile myelomonocytic leukemia.
    Park HD; Lee SH; Sung KW; Koo HH; Jung NG; Cho B; Kim HK; Park IA; Lee KO; Ki CS; Kim SH; Yoo KH; Kim HJ
    Ann Hematol; 2012 Apr; 91(4):511-7. PubMed ID: 21901340
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Recent advances in the pathogenesis and management of juvenile myelomonocytic leukaemia.
    Koike K; Matsuda K
    Br J Haematol; 2008 May; 141(5):567-75. PubMed ID: 18422786
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Quantification of granulocyte-macrophage colony-stimulating factor hypersensitivity in juvenile myelomonocytic leukemia by 3H-thymidine assay.
    Tanaka M; Takahashi Y; Xu Y; Yoshida N; Yoshimi A; Villalobos IB; Hama A; Nishio N; Hidaka H; Wang Y; Yagasaki H; Kojima S
    Leuk Res; 2008 Jul; 32(7):1036-42. PubMed ID: 18164384
    [TBL] [Abstract][Full Text] [Related]  

  • 15. RAS Pathway Mutation Patterns in Patients With Juvenile Myelomonocytic Leukemia: A Developing Country Single-center Experience.
    Hamdy N; Bokhary H; Elsayed A; Hozayn W; Soliman S; Salem S; Alsheshtawi K; Abdalla A; Hafez H; Hammad M
    Clin Lymphoma Myeloma Leuk; 2020 Jul; 20(7):e368-e374. PubMed ID: 32209330
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Juvenile myelomonocytic leukemia: who's the driver at the wheel?
    Niemeyer CM; Flotho C
    Blood; 2019 Mar; 133(10):1060-1070. PubMed ID: 30670449
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Juvenile myelomonocytic leukemia - A bona fide RASopathy syndrome.
    Lasho T; Patnaik MM
    Best Pract Res Clin Haematol; 2020 Jun; 33(2):101171. PubMed ID: 32460983
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Activating FLT3 mutations are rare in children with juvenile myelomonocytic leukemia.
    Gratias EJ; Liu YL; Meleth S; Castleberry RP; Emanuel PD
    Pediatr Blood Cancer; 2005 Feb; 44(2):142-6. PubMed ID: 15390271
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Mutations of an E3 ubiquitin ligase c-Cbl but not TET2 mutations are pathogenic in juvenile myelomonocytic leukemia.
    Muramatsu H; Makishima H; Jankowska AM; Cazzolli H; O'Keefe C; Yoshida N; Xu Y; Nishio N; Hama A; Yagasaki H; Takahashi Y; Kato K; Manabe A; Kojima S; Maciejewski JP
    Blood; 2010 Mar; 115(10):1969-75. PubMed ID: 20008299
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Molecular biology of juvenile myelomonocytic leukemia (JMML)].
    Manabe A
    Rinsho Ketsueki; 2010 Jul; 51(7):526-31. PubMed ID: 20693772
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 15.